DivestmentMay 13, 2026, 04:03 PM
MacroGenics Divests Manufacturing, Monetizes ZYNYZ Royalty for $202.5M
AI Summary
MacroGenics reported Q1 2026 financial results and announced strategic steps to sharpen its focus on novel drug discovery. The company is divesting its GMP manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million and expanded the monetization of ZYNYZ royalties with Sagard Healthcare Partners for $60.0 million cash, with a potential additional $20.0 million. These actions are expected to provide up to $202.5 million in combined proceeds and extend the cash runway through 2028.
Key Highlights
- Divested GMP manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million.
- Expanded ZYNYZ royalty monetization with Sagard Healthcare Partners for $60.0 million cash, plus potential $20.0 million milestone.
- Combined proceeds of up to $202.5 million from divestiture and royalty monetization.
- Extended cash runway guidance through 2028.
- Q1 2026 total revenue increased to $20.8 million from $13.2 million YoY.
- Q1 2026 net loss was $36.8 million, improved from $41.0 million YoY.
- Q1 2026 R&D expenses decreased to $35.0 million from $39.7 million YoY.
- Anticipates initial MGC026 clinical data in mid-2026 and MGC028 data in H2 2026.
Price Impact
More from MGNX